Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alvin Ong

Orthopaedic Surgery Egg Harbor Township, NJ Medical Doctor

NPI 1992759138 CMS profile 960954

2500 English Creek Ave, Building 1300, Egg Harbor Township, NJ 08234

Open in the dashboard

General payments

$698,708

556 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$144,832 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Alvin Ong of Egg Harbor Township, NJ is reported in the CMS Open Payments database as having received $698,708 across 556 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $144,832 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79,107 87
2024 General $65,074 76
2023 General $105,591 88
2022 General $132,058 89
2021 General $99,518 72
2020 General $65,293 26
2019 General $152,067 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alvin Ong
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Alvin Ong were reported at $79,107. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Alvin Ong Orthopaedic Surgery median Middle half National median
2019 $152,067 $644 $140–$2,844 $163
2020 $65,293 $312 $75–$1,860 $114
2021 $99,518 $520 $117–$2,495 $132
2022 $132,058 $598 $128–$2,731 $149
2023 $105,591 $461 $128–$2,264 $160
2024 $65,074 $497 $134–$2,475 $164
2025 $79,107 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $440,754 212 payments
  2. Stryker Corporation $256,936 314 payments
  3. DePuy Synthes Sales Inc. $201 5 payments
  4. Zimmer Biomet Holdings, Inc. $174 4 payments
  5. Pacira Pharmaceuticals Incorporated $143 2 payments
  6. Becton, Dickinson and Company $129 3 payments
  7. Davol Inc. $52 1 payment
  8. Globus Medical, Inc. $48 1 payment
  9. Medacta USA, Inc. $46 1 payment
  10. Baxter Healthcare $35 1 payment
  11. Other $190 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $275,869 78 payments
  2. Royalty or License $175,648 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $165,205 43 payments
  4. Travel and Lodging $68,329 156 payments
  5. Food and Beverage $13,657 261 payments
Products named General payments · program years 2019–2025
  1. MAKO $177,553 154 payments
  2. Journey II BCS $99,806 56 payments
  3. LEGION Recon Knees $92,976 10 payments
  4. Legion Recon Knees $78,320 16 payments
  5. LEGION TKS Recon Knees $48,141 6 payments
  6. LEGION Revision Recon Knees $43,709 18 payments
  7. LEGION TKS Recon Knees $43,252 6 payments
  8. ACCOLADE $42,942 38 payments
  9. REAL INTELLIGENCE $36,944 35 payments
  10. Legion Revision Recon Knees $34,054 45 payments
  11. Other $506,613 412 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

843

Median for Orthopedic Surgery: 203

Drug cost

$6,153

Median for Orthopedic Surgery: $1,433

Branded share of claims

5.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 173 $2,431
Clobetasol Emollient Clobetasol Propionate/Emoll Brand 23 $1,358
Oxycodone Hcl Generic 122 $897
Clindamycin Hcl Generic 248 $450
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $310
Cyclobenzaprine Hcl Generic 36 $267
Prednisone Generic 117 $216
Methylprednisolone Generic 15 $82
Tramadol Hcl Generic 27 $68
Meloxicam Generic 28 $46

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$583,804

Of which drugs: $10,764

Medicare patients

921

Average age 74

Services billed

5,624

541 women, 380 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 28%
Chronic kidney disease 19%
Atrial fibrillation 17%
Depression 17%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 23 1,500 $8,151
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 249 1,368 $1,028

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

556 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record